Table 1 Esophagus
Author | Cases n | Controlsa/Cohortb | Source population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
|---|---|---|---|---|---|---|---|---|
Coogan et al. [26] | 207 | 5,833a | Hospital based | >4 days/week for >3 months. Continuing use during 1 year of lag time | Personal Interview | NSAIDs (7%) | 0.8 | 0.5–1.4 |
Farrow et al. [30] | 277 | 687a | Population based | >1 tablet/week during >6 months. 1 year lag time | Personal Interview | Aspirin (31%) | 0.48†| 0.32–0.70 |
|  | 279 |  |  |  |  | NA-NSAIDs (13%) | 0.81†| 0.51–1.30 |
Langman et al. [36] | 550 | 1,650a | Population based | >7 prescriptions during months 13–36 before index date | Automated Database | NSAIDs (8%) | 0.64 | 0.41–0.98 |
Garidou et al. [32] | 56 | 200a | Hospital based | Chronic intake | Personal Interview | NSAIDs (14%) | 0.52†| 0.17–1.62 |
Suleiman et al. [59] | 56 | 56a | Population based | Ever use for >1 year | Medical records | NSAIDs (38%) | 0.16 | 0.03–0.93 |
Cheng et al. [60] | 74 | 74a | Population based | Ever daily use for >1 month | Personal Interview | Aspirin (21%) | 0.67 | 0.27–1.63 |
Funkhouser et al.31 | 15 | 13,179b | Cohort | Use 30 days before baseline (ocasional) | Personal Interview | Aspirin (51%) | 0.10 | 0.01–0.76 |
Thun et al. [46] | 157 | 635,031b | Cohort | More than 16 times per month for at least one year | Mailed questionnaire | Aspirin (11%) | 0.59 | 0.34–1.03 |
-
Prevalence of exposure among controls/cohort; †Adenocarcinoma.